The tremor in patients with anxiety was supposed to be an enhanced physiological tremor. However no detailed clinical and electromyographic examination of tremor in patients with anxiety has been published. It has been also supposed that propranolol or benzodiazepines may influence the tremor The aim of this investigation was to establish the clinical and electromyographic pattern of tremor in patients with anxiety and to compare the effects of propranolol and alprazolam treatment. One hundred and twenty patients with tremor and generalized anxiety disorder were investigated. Tremor was scored clinically by the Webster Tremor Scale. Electromyographic examination of tremor activity from antagonistic hand muscles was performed. Sixty patients were treated with alprazolam and propranolol, in an open, crossover design, while the other sixty patients received no particular treatment for the tremor The patients were randomly assigned to treatment with propranolol, alprazolam, or received no tremor treatment. Our results revealed a postural and kinetic tremor with characteristics of an enhanced physiological tremor. Tremor involved only upper limbs and no other body parts. Treatment with propranolol or alprazolam had similar favorable effect on tremor. In conclusion tremor in generalized anxiety disorder is an enhanced physiological tremor The kinetic tremor disturbs patients and particular tremor treatment with propranolol or alprazolam should be applied.
Download full-text PDF |
Source |
---|
Mymensingh Med J
January 2025
Dr Mohammad Masum Emran, Junior Consultant (Neurology), RMO, Cumilla Medical College Hospital, Cumilla, Bangladesh; E-mail:
Parkinson's disease (PD) is a common neurodegenerative disorder. The pathogenesis of PD is unknown till now. The high-sensitivity C-reactive protein (CRP) is a non-specific biochemical marker of inflammation.
View Article and Find Full Text PDFCurr Top Behav Neurosci
December 2024
Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Cannabis-based medicine (CBM) is used in a wide variety of different neurological disorders. While the use of CBM in the treatment of pain, AIDS wasting, loss of appetite, and spasticity is well established, CBM application in movement disorders and neurodegenerative disorders is still an emerging topic. The purpose of this chapter is to summarize current evidence behind the use of CBM in selected neurological diseases, mainly movement and neurodegenerative disorders.
View Article and Find Full Text PDFFront Bioeng Biotechnol
December 2024
Center for Healthcare Robotics, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Introduction: During tasks like minimally invasive surgery (MIS), various factors can make working environment not be ergonomic, and those situations will accumulate fatigue in the surgeon's muscles which will inevitably lead to poor surgical performance. Therefore, there has been a need for technical solutions to solve this problem and one of the methods is exoskeleton robots.
Methods: We designed a passive shoulder exoskeleton whose workspace could be used for MIS to assist the surgeon's movements and performed computational and clinical validation.
AACE Clin Case Rep
August 2024
Department of Endocrinology, Endocrine ParaThyroid Center, Norman, Oklahoma.
Background/objective: 4H syndrome is a rare form of leukodystrophy characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism. In 95% of cases, hypomyelination is present, but other clinical features, such as hypodontia and hypogonadotropic hypogonadism, are not always present and may not be necessary for diagnosis. Hypogonadotropic hypogonadism is the most common endocrine complication that can occur in 4H syndrome.
View Article and Find Full Text PDFParkinsonism Relat Disord
December 2024
Amneal Pharmaceuticals, LLC, 400 Crossing Boulevard, Bridgewater, NJ, USA.
Background: For Parkinson's disease patients with motor fluctuations, the duration of benefit per levodopa dose is a key metric that reflects a patient's clinical response.
Objective: Determine the difference in mean durations of "Good On" time per dose of subjects randomized to extended-release carbidopa-levodopa (ER CD-LD; IPX203; CREXONT®) vs. immediate-release (IR) CD-LD in the RISE-PD trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!